Dr. Max runs a Korean-cosmetics category in its Czech and Slovak pharmacies carrying around 500 products, and about 100 in Italy. Beauty of Joseon sits in roughly 600 of Drogasil's 2,000 Brazilian stores. Apotek Hjärtat in Sweden and Life Pharmacy in the UAE run Korean skincare categories on their online stores. None of these is a beauty retailer. The second overseas shelf K-beauty has opened this cycle is staffed by pharmacists, and it does not buy on trend. Which pharmacy chains are carrying Korean cosmetics? The pattern spans four continents and does not run through a single Korean company. In Czechia, Dr. Max carries a Korean-cosmetics category of around 500 products including COSRX, Anua, SKIN1004 and Dr. Jart+. Its Slovak operation runs a category of similar size and its Italian operation about 100 products. In Sweden, Apotek Hjärtat operates a Korean skincare category online carrying COSRX, Anua and TIRTIR. In the UAE, Life Pharmacy runs a Korean beauty category online that includes APR's beauty devices alongside Beauty of Joseon, SKIN1004 and COSRX. In Brazil, Beauty of Joseon entered roughly 600 Drogasil stores. In Georgia, the same brand entered PSP Pharma in October 2026 with around 20 products, among them a rice sunscreen, a ginseng serum and a face cream. Two clarifications are worth making early, because the figures circulate in garbled form. The 500 in Czechia counts products, not pharmacies. The 600 in Brazil counts stores, not products. These counts were reported in October 2026 and the chains have not published them individually. A Dr. Max pharmacy in Czechia. The group says it runs more than 3,300 pharmacies across six core markets. Photo: V0lkanic, CC BY 4.0, via Wikimedia Commons. How large are these networks? Dr. Max Group states that it operates more than 3,300 pharmacies as it entered the second half of 2026, with a joint-venture interest in a further 580 or so, across six core markets: Czechia, Slovakia, Romania, Poland, Italy and Serbia. It reports 2025 revenue of €6.3 billion, up 14.7%, says it expects to exceed €7 billion in 2026, and employs more than 22,000 people. The company also describes itself as Europe's largest pharmacy chain by number of pharmacies; that is the group's own characterisation of its position. Drogasil reached 2,000 pharmacies in operation in Brazil during 2025. It is one of two banners operated by RD Saúde, which reports more than 3,300 stores across Drogasil and Raia combined and a presence in every Brazilian state. Dr. Max reports more than 3,300 pharmacies and Drogasil passed 2,000 in 2025. A category decision at this scale moves more units than a flagship. Scale is the first reason this channel is not a curiosity. A category decision taken once at a chain of this size reaches more doors than most brands assemble through specialty retail in several years, and it reaches them without a local entity, a flagship or a marketing budget per market. Why does a pharmacy abroad sell skincare at all? This is where Korean intuition misleads, and it is the reason the development has been under-read from Seoul. A Korean pharmacy is typically a small independent business built around dispensing and over-the-counter medicines, with cosmetics a negligible share of the floor. The word carries that image. The overseas chains in question are large-format retail. They carry medicines alongside skincare, suncare, personal care and household goods, with the buying function, private-label programmes and category management of a retail group. Dr. Max's €6.3 billion of 2025 revenue is not a dispensary number. When these businesses create a Korean-cosmetics category, they are making the same kind of decision a drugstore chain makes, not the kind a chemist makes. So the phrase pharmacy channel means something different in Seoul than it does in Prague or São Paulo, and the gap in meaning is roughly the size of the opportunity. A Droga Raia pharmacy in Brazil. Raia and Drogasil are the two banners run by RD Saúde. Photo: Eduardo P, CC BY-SA 3.0, via Wikimedia Commons. What is the pharmacy shelf actually selling? Goodai Global's account of why the channel matters is that pharmacies abroad are understood as places selling products a pharmacist has vetted, so a listing signals that the product was accepted by the distribution network local consumers trust most. That is the company's framing of its own entry, and it is the correct description of the mechanism even allowing for the source. The distinction from a beauty retailer is not about prestige. It is about what the buyer is underwriting. A beauty retailer underwrites interest: the question is whether the product will sell this season, and the curator's own authority is what the shopper is responding to. A pharmacy underwrites suitability: the question is whether the product holds up, because a pharmacist who recommends it is lending professional standing to the recommendation. A beauty buyer asks whether a product will sell. A pharmacy buyer asks whether it holds up. The second question is slower to answer either way. That changes the shape of the risk. A beauty listing can end after one soft quarter or one change of editorial direction. A pharmacy category, once established and once the staff are comfortable recommending from it, turns slowly in both directions. It is harder to enter and harder to be removed from. What demand is this channel answering? The pharmacy shelf did not invent a category; it grew into one that was already expanding. Euromonitor puts the global dermocosmetics market at about US$20.82 billion in 2020 and about US$36.94 billion in 2025, a rise of 77.4%. Global dermocosmetics grew 77.4% between 2020 and 2025, to US$36.9 billion. The pharmacy entries follow the money rather than leading it. The behaviour underneath that number is consumers comparing named actives and claimed effects rather than brands — ceramides, cica, PDRN — which is a mode of shopping a pharmacy is organised to serve and a beauty hall is not. Korean formulations arrived at that conversation with an ingredient-led vocabulary already built, which is why the category found them rather than the other way round. Which Korean companies are inside this channel? The named brands cluster more than the geography suggests. COSRX appears in Dr. Max in Czechia, in Apotek Hjärtat and in Life Pharmacy. Anua appears in the first two. SKIN1004 appears in Dr. Max and Life Pharmacy. Beauty of Joseon is in Life Pharmacy, Drogasil and now PSP Pharma. TIRTIR is in Apotek Hjärtat. APR sits in Life Pharmacy with devices rather than skincare, and Dr. Jart+, owned by Estée Lauder, appears in Dr. Max. Several of those listings share an owner. Goodai Global holds Beauty of Joseon, TIRTIR and SKIN1004 among its brands, so a channel that looks like a broad industry movement is in part one house of brands appearing repeatedly under different names. That is a meaningful qualification to any reading of the channel's breadth. Can the channel's contribution be sized from what is public? No, and the gap is worth stating plainly rather than filling with estimates. What is on the record about Goodai Global is mostly capital, not trading. The company raised 800 billion won — US$601 million at the 16 October 2026 Seoul rate of 1,331.4 won to the dollar, which is the rate used throughout this article — from IMM Private Equity, JKL Partners, Premier Partners, Kiwoom Private Equity and Company K Partners, reported in December 2025 at a valuation put at US$3.1 billion. The company said in early February 2026 that it had acquired Hansung USA, a distributor of Korean beauty brands to American offline retailers; the price of about 100 billion won (US$75 million) and the controlling stake were attributed to investment-banking sources rather than to a filing, and the reporting did not state whether the transaction had closed. Hansung USA's revenue was reported at about 170 billion won (US$128 million) for 2025 against about 80 billion won (US$60 million) for 2024, with no source named for either figure. The listing picture is looser still. Goodai was reported to have sent a request for proposal to around 14 securities firms late in 2025 and to have shortlisted five domestic and six foreign houses. Financial investors have been reported as targeting more than 10 trillion won — US$7.5 billion — in an eventual listing, a figure sitting several times above the valuation reported ten months earlier and supported by no filing. Company statements have put the intention at a listing within three years; press accounts have placed it variously in 2026 and as late as 2028. Against that, the pharmacy entries carry no disclosed revenue at all — not a figure per chain, not a share of sales, not a growth rate. The channel is visible in store counts and product counts and invisible in financials. Anyone sizing its contribution right now is estimating. What does a pharmacy buyer require that a beauty buyer does not? A dossier, principally. Claim substantiation that survives a pharmacist being asked a direct question across a counter, ingredient documentation that matches the regulatory file in that specific market, and supply stability, because a pharmacy category that runs out teaches staff to stop recommending from it. Those requirements fall unevenly across the industry. They favour companies whose manufacturing partners already hold the certifications and assemble the documentation — which in Korean practice usually means the large ODMs — and they penalise brands whose proposition is packaging, a creator partnership or speed to a trend. The channel is open to K-beauty generally and to a narrower set of Korean companies specifically. Where does this leave the industry? For manufacturers, the dossier is becoming the product. A channel that buys on substantiation shifts value toward whoever can produce and maintain the evidence file per market, and that capability sits with the contract manufacturer more often than with the brand. For brands and buyers, a second shelf has opened with a different failure mode from the first. The beauty retailer shelf is faster to win and faster to lose; the pharmacy shelf is slower at both ends. Treating them as interchangeable distribution is a planning error, because the inventory, documentation and support commitments behind them are not the same commitments. For regulators and investors, the channel is currently unmeasurable. Store counts and product counts exist, revenue does not, and a company reported to be approaching a listing at a valuation several times what it carried ten months earlier has not disclosed what any of this sells. The pharmacy shelf is real. Its contribution is not yet a number.

Head & Shoulders announced its Scalp Care Collection on October 15, 2026, fronted by niacinamide, bio-ceramides and a proprietary HydraSC+ Complex. That complex is built on 1.8 percent salicylic acid or 1 percent zinc pyrithione. In the United States both are over-the-counter drug actives, and 1.8 percent is the exact floor of the range the federal monograph permits. The vocabulary of the launch is skincare. The chemistry is a drug, and a drug label is a closed list of sentences. The Head & Shoulders Scalp Care Collection: Soothe (itchy scalps), Purify (oily scalps) and Restore (dry scalps). Source: Head & Shoulders / P&G press kit, October 2026. The same 1 percent zinc pyrithione is a drug active in the United States, a capped cosmetic ingredient in Korea, and prohibited in the European Union. What is actually inside the HydraSC+ Complex? Two ingredients that have been in dandruff products for decades. Zinc pyrithione, which the company's announcement describes as targeting Malassezia, the scalp microbe associated with dandruff, and salicylic acid, which lifts flakes and buildup by exfoliating. The announcement gives one concentration for each: 1 percent and 1.8 percent. It gives no concentration for niacinamide or for the bio-ceramides, the two ingredients the collection is named after. The collection runs across three regimens. Scalp Soothe with niacinamide covers a cooling shampoo and a cooling scalp spray, aimed at itch. Scalp Purify with salicylic acid covers a clarifying pre-shampoo and a volumizing shampoo, aimed at oil. Scalp Restore with bio-ceramides covers a nourishing shampoo, conditioner and leave-on serum, sulfate-free, aimed at dryness. The announcement names salicylic acid for the Purify regimen and does not say which regimens carry the zinc pyrithione. Niacinamide, salicylic acid and bio-ceramides front the three regimens, and a monograph drug active sits under all of them. Why does that chemistry make this a drug rather than a cosmetic? Because in the United States the ingredient determines the category. A cosmetic cleanses or beautifies; a drug is intended to treat or prevent a condition. Dandruff is a condition, and the Food and Drug Administration lists the ingredients that can be used against it in 21 CFR 358.710: coal tar at 0.5 to 5 percent, pyrithione zinc at 0.3 to 2 percent in products washed off after brief exposure, salicylic acid at 1.8 to 3 percent, selenium sulfide at 1 percent, sulfur at 2 to 5 percent. A product built on those actives is an over-the-counter drug, registered and labeled as one. Head & Shoulders already files this way. A current Head & Shoulders shampoo listed with the FDA shows pyrithione zinc 1 percent as its active ingredient, the purpose line "Anti-dandruff," the use "fights recurrence of the symptoms of dandruff," the marketing category "OTC Monograph Drug" under monograph M032, and The Procter & Gamble Manufacturing Company as labeler. Those bottles carry a Drug Facts panel, not an ingredient list. The placement of 1.8 percent is worth pausing on. The monograph range for salicylic acid runs 1.8 to 3 percent, so the formula sits on the lowest concentration at which the claim is available at all. The 1 percent zinc pyrithione sits in the lower half of its wash-off range of 0.3 to 2 percent, and just above the 0.95 percent floor the monograph sets for seborrheic dermatitis. A pharmacist takes a boxed drug off the shelf. In the United States a dandruff shampoo built on these actives is registered and sold as a drug. Photo by National Cancer Institute on Unsplash. What is the label allowed to say? Very little, and the wording is prescribed. Under 21 CFR 358.750, the indications statement must read "For relief of" or "Controls" plus "the symptoms of" plus dandruff, seborrheic dermatitis or psoriasis. The regulation permits a short list of substitutions: "fights," "reduces," "helps eliminate," "helps stop," "controls recurrence of," "helps prevent recurrence of." In place of "the symptoms of" a label can name skin or scalp plus itching, irritation, redness, flaking or scaling, followed by "associated with." Other statements are permitted only where they describe indications already established in that list. That is the entire vocabulary of an anti-dandruff drug claim in the United States. It has no room for barrier repair, no room for moisture duration, and no room for volume. The Scalp Care Collection campaign banner. Source: Head & Shoulders website. Where do the launch claims live, then? Outside it. The announcement says the Purify regimen instantly removes up to 99 percent of flakes, oil and buildup and delivers up to 5 times more volume. It says the Restore regimen provides a 72-hour moisture lock and restores the scalp barrier. It says the Soothe regimen delivers instant cooling and itch relief from first use and adds shine. Flaking and itching are monograph territory. Oil, buildup, volume, moisture duration, barrier restoration and shine are not. Those are cosmetic claims riding on a drug product, which is a legitimate and common structure. It also explains the shape of the launch. The drug layer is frozen: every competitor using the same actives can make the same anti-dandruff statement in the same words, and no amount of formulation changes that. Differentiation has to happen in the layer the monograph does not reach, which is exactly where niacinamide, bio-ceramides and the word scalp sit. Anti-dandruff wording is a closed list in federal regulation. Every claim the launch is built on sits outside that list. What does the leave-on format change? The arithmetic. The monograph treats a product left on the skin or scalp as a different product from one rinsed off after brief exposure, and it caps leave-on pyrithione zinc at 0.1 to 0.25 percent against 0.3 to 2 percent for wash-off. The gap is roughly eightfold at the top, and it exists because exposure time, not concentration alone, determines dose. The collection includes two leave-on formats: a cooling scalp spray the announcement says can be used up to four times daily between washes, and a nourishing leave-on serum. The announcement does not state whether either contains a monograph active. If they do, they sit under the leave-on ceiling rather than the wash-off one. If they do not, they are cosmetics sold alongside drugs in the same regimen, which is a labeling and claim question rather than a safety one. What happens to the same formula outside the United States? It changes legal identity twice. In Korea, zinc pyrithione is a restricted cosmetic ingredient under the cosmetic safety standards rather than a drug active. It is permitted at 0.5 percent as a preservative in rinse-off products, and at a total of 1.0 percent in rinse-off anti-dandruff and anti-itch products such as shampoos and rinses and in products for relief of hair-loss symptoms. It is prohibited in everything else. A 1 percent wash-off formula is therefore legal in Korea at its ceiling, and it is a cosmetic there, not a drug. Salicylic acid runs the same way. Korea permits 0.5 percent as a preservative, 2 percent in body cleansing products and 3 percent in rinse-off hair products, restricting non-preservative use to functional cosmetic active ingredients, and prohibiting it in products specified for infants or children aged 13 and under, with shampoo excepted. In the European Union, zinc pyrithione is not permitted in cosmetics at any concentration. Regulation (EU) 2021/1902 of November 3, 2021 moved it to the prohibited list with effect from March 1, 2022, following a reproductive toxicity category 1B classification. The Scientific Committee on Consumer Safety found in March 2020 that shampoo containing under 1 percent was safe, but a CMR substance stays banned unless it is also shown to be irreplaceable, and that was not demonstrated. Before the ban it had been allowed at up to 1 percent in rinse-off products as a preservative. One molecule, three regulatory identities: a drug active in the United States, a capped cosmetic ingredient in Korea, and a banned substance in Europe. A global scalp care platform built on it is three different product development programs wearing one brand name. Which statements here are regulatory facts and which belong to the company? The concentration limits, the permitted wordings and the EU prohibition are published law. Almost everything else in the announcement is the company's own. The flake-removal claim is described as clinically proven, and the announcement names no study, sample size or method. The brand is described as the world's number one anti-dandruff shampoo and the number one United States dermatologist recommended anti-dandruff brand, both company statements. The most-awarded scalp care brand claim carries a footnote defining its own universe: total awards from United States beauty, grooming and lifestyle publications and websites within the Nielsen scalp-care segment between 2017 and 2026. Matt Krehbiel, vice president for Head & Shoulders, said the launch marks a bold new chapter for the brand and that exceptional hair starts at the scalp. What does US$11.99 ask of a mass shelf? Shampoos and conditioners carry a suggested price of US$11.99, available at Walmart, with treatments and wider distribution following in November 2026. That price asks a mass drugstore and supercenter shopper to pay a prestige-adjacent figure for a product in the aisle where dandruff shampoo has been a value purchase for decades. The category data makes that a reasonable bet and an exposed one. United States mass beauty grew 7 percent in the first half of 2026 to US$39.2 billion, according to Circana, with mass hair care also up 7 percent in dollars while units dipped, meaning price rather than volume carried the growth. Prestige hair care grew 11 percent in dollars on 8 percent unit growth over the same period. A mass brand raising its price point is following where the dollars went. It is also testing whether a shopper who has been trained for decades to buy this product on price will re-evaluate it on vocabulary. A mass-market drugstore aisle where every shelf edge carries a price tag. Mass hair care grew 7 percent in dollars in the first half of 2026 while units dipped. Photo by Cheung Yin on Unsplash. What does the rest of the industry take from this? Three positions read the same filing differently. Manufacturers and formulators. A scalp platform that travels internationally cannot be one formula. The actives that define the category in the United States are capped at a different level in Korea and unavailable in Europe, which means separate formulas, separate substantiation files and separate claim sets per region. The branding is global; the chemistry is not. Brands and buyers. When the drug layer is a fixed and shared vocabulary, competitive advantage has to be built in the cosmetic layer around it. That is a marketing and substantiation contest rather than a formulation one, and it is winnable by companies with no monograph expertise at all. Regulators and investors. A product that reads as skincare and files as a drug sits under two claim regimes at once. The monograph claim is protected and inflexible. Everything stacked on top is an ordinary cosmetic claim, enforceable as advertising, and it is where the entire repositioning rests. The actives did not change. The sentences around them did. In this category the sentences are the product development.

Shoppers stroll past the Douglas store entrance in Bologna, Italy Douglas named Jean-Marc Bellaiche chief executive on October 14, 2026, effective November 1 for a four-year term. The announcement runs through omnichannel retail, luxury credentials and supply chain reorganization. It makes no mention of Korea, of Asia, or of Korean beauty. In the same fiscal year, Korean cosmetics exports to Europe passed exports to North America for the first time on a half-year basis. Europe's largest beauty retailer is changing its chief executive in the middle of the fastest shift its category has seen, and the shift is not in the announcement. Douglas cut its full-year adjusted EBITDA margin guidance twice during 2026, from about 16.5 percent to about 15.0 percent. What do the numbers behind the appointment say? Douglas runs about 1,970 stores in 22 countries, where like-for-like sales fell 4.5 percent in the quarter ended June 30, 2026. Photo by balesstudio on Unsplash. Douglas reported third-quarter results for the period ended June 30, 2026 on August 12. Group sales were €987.8 million, down 2.0 percent. Like-for-like sales, which strip out stores opened and closed during the period and so measure the same selling space against itself, fell 4.5 percent. Adjusted EBITDA was €127.5 million, down 19.4 percent, at a margin of 12.9 percent. E-commerce accounted for 33.1 percent of quarterly sales, up 0.4 percentage points. The gap between the two sales lines is the part worth holding onto. Reported sales fell 2.0 percent while like-for-like sales fell 4.5 percent, which means the store estate masked a steeper decline in the shops that were open in both periods. The group operates around 1,970 stores across 22 European countries and reported sales of €4.58 billion in fiscal 2024/25, with more than 19,900 employees. Its fiscal year ends September 30. How many times did the guidance move? Twice, in one direction. Douglas entered the year guiding to an adjusted EBITDA margin of around 16.5 percent on sales of €4.65 billion to €4.80 billion. On April 30, 2026, reporting second-quarter sales of €949.7 million and adjusted EBITDA of €116.1 million, it cut the margin guidance to around 16.0 percent and said sales would land at the lower end of the range, citing changes in the premium beauty market and the geopolitical and economic environment. On August 12 it set full-year guidance at 0 to 1 percent sales growth, €4.58 billion to €4.63 billion, with an adjusted EBITDA margin of around 15.0 percent. That final range sits below where the year started on both lines. A company guiding to flat sales at a compressed margin is a company whose incoming chief executive inherits a cost problem before he inherits a growth problem. What does 3.1 times net leverage constrain? Net leverage is net debt divided by adjusted EBITDA, and it is the ratio lenders write covenants against. Douglas reported 3.1 times at June 30, 2026 including lease liabilities, and 2.2 times before them. Full-year guidance puts the September 30, 2026 figure at 3.0 to 3.5 times. The denominator is the issue. Leverage of 3.1 times on EBITDA that fell 19.4 percent in the quarter is a different position from 3.1 times on EBITDA that is growing, because the ratio deteriorates without a single euro of new borrowing. That arithmetic sets the boundary on what any new chief executive can spend on category expansion, store renovation or exclusive brand deals in the first year. It does not forbid investment. It forces investment to be argued against near-term margin. Who is Bellaiche, and what does his record point at? Bellaiche is 56 and French. He began at Boston Consulting Group in 1993 and became managing director and global leader of its luxury, fashion and beauty sector. He joined Tiffany & Co. in 2014 as senior vice president and an executive committee member, then held senior and board roles at the technology companies Contentsquare and Arianee. He ran Printemps Group as chief executive from 2020 on a five-year mandate, and spent the past year as chief executive of the luxury resort operator Sani/Ikos Group. The through-line is luxury positioning and department store economics, not mass or masstige assortment management. Sander van der Laan, who joined in October 2022 and retires after a 36-year career, is credited by the company with the shift to omnichannel, a supply chain reorganization and an ESG strategy. Supervisory Board Chairman Dr. Henning Kreke described him as "an outstanding leader and highly experienced retail executive." Those are the company's own characterizations of its own departing executive, and they should be read as such. What changed in European demand while this was happening? Korean cosmetics exports to Europe reached US$1.596 billion in the first half of 2026, against US$1.570 billion to the United States and Canada, according to Korea Customs Service data. That is the first half-year in which Europe took more Korean cosmetics than North America. The annual series shows the slope: US$1.092 billion in 2023, US$1.413 billion in 2024, US$2.049 billion in 2025. Korean cosmetics exports to Europe nearly doubled between 2023 and 2025, and Europe passed North America in the first half of 2026. A category that doubles in two years does not stay unassigned on a retailer's floor plan. Someone takes the space, and the retailer that takes it first sets the terms with the brands that fill it. What has Douglas actually committed to the category? Two confirmed locations. Douglas ran an exclusive Beauty of Joseon pop-up at its Düsseldorf store, described in reporting from late July 2026 as going beyond brand listing into joint marketing. Its renovated 750 square meter Amstelveen flagship, covered in August 2026, includes what the coverage calls an expansive K-Beauty Zone alongside a niche fragrance wall carrying Tom Ford, Armani Privé and Maison Margiela. What has not been published is everything that would make those two data points into a position: how many of the roughly 1,970 stores carry a Korean assortment, which brands, on what commercial terms, with what exclusivity. Douglas's own newsroom and quarterly releases do not quantify the category. Absence of disclosure is not absence of activity, and nothing here establishes that Douglas lacks a plan. It establishes that the plan is not on the record. What have competitors put on the record instead? Korean cosmetics exports to Europe reached US$1.596 billion in the first half of 2026, passing North America for the first time. Photo by Omar Lopez on Unsplash. Numbers, mostly in store counts. Beauty of Joseon moved from 120 Boots locations in the United Kingdom to around 1,300, and entered Rossmann and Hebe in Poland. APR's Medicube entered Sephora's European online store and about 450 physical stores across 17 European countries in phases during 2026. John Lewis signed an exclusive partnership with the distributor Skin Cupid in April 2026 and opened a Korean beauty shop-in-shop with 20 brands, including Beauty of Joseon, Medicube and Anua, with some products sold only there. D'Alba entered all of Primor's roughly 200 Spanish stores and Costco in France and Spain. Competitors describe Korean beauty in store counts across markets. Douglas's confirmed footprint is a pop-up and a zone in one flagship. The distinction is between a destination and a demonstration. A shop-in-shop with exclusive brands is a commitment that a distributor can plan supply against. A zone in one renovated flagship is a test of a fixture. Both are legitimate decisions. They produce different negotiating positions when a brand chooses where to place a European launch. Is the omission a strategy or an oversight? A chief executive announcement is a positioning document aimed at investors, and it names the priorities the supervisory board wants attached to the new appointment. Nothing requires it to list every category. But the release does name priorities, and the ones it names are omnichannel execution, luxury expertise and operational discipline. Read against the guidance path and the leverage ratio, that selection is coherent rather than careless. A board facing a 19.4 percent fall in quarterly adjusted EBITDA and a covenant ratio that worsens on its own recruits for margin recovery, and it recruits someone who has run premium positioning at Printemps and Tiffany. The cost of that coherence is that the category growing fastest in the retailer's home region is being handled as an assortment question rather than a strategic one, while competitors treat it as a format question and build fixtures for it. What does the rest of the industry take from this? Three readings sit on the same disclosures. Manufacturers and ODMs. European volume is now being set by drugstore and department store chains committing hundreds to thousands of doors at a time, not by prestige perfumeries testing zones. Capacity planning follows the retailer that publishes a store count. Brands and distributors. A retailer under margin pressure is a harder counterparty on terms and a slower one on decisions, but it is also the one with open space on its floor plan. The European entry question is no longer which chain has the most stores. It is which chain has already assigned the square meters. Investors and lenders. Leverage at 3.1 times with EBITDA contracting is the constraint that decides whether category investment happens at all. Any assessment of a European beauty retailer's exposure to Korean demand has to start with what the covenant allows, not with what the trend data suggests. Douglas has four years of a new chief executive and one fiscal year of guidance already cut twice. The category that doubled in Europe in two years is not waiting for either clock. Shelf space gets assigned once.

Korea's cosmetics exports reached US$11.1 billion in the first nine months of 2026, up 31.1 percent, with the United States taking US$2.35 billion of that. When the Minister of SMEs and Startups toured Kolmar Korea's Sejong plant on Friday, October 16, the company that fills those units named its largest problem, and it was neither capacity nor tariffs. It was counterfeits on overseas platforms. The company that raised it owns no trademark on anything it makes. What did the manufacturer actually tell the minister? Minister Lee So-young spent the visit on the floor of a plant run by an ODM, an original design manufacturer, meaning a contractor that both develops the formulation and produces it under a client's brand name. Kolmar Korea was founded in 1990 and the brands named at the plant included Beauty of Joseon and d'Alba. Chief executive Choi Hyun-kyu named the spread of counterfeit cosmetics overseas as K-beauty's single biggest concern, and said small indie brands exporting to North America and Europe are struggling with copies of their products in those markets. He pointed to counterfeits of Beauty of Joseon and APR products that the Korean Intellectual Property Office had recently detected. Shim Jae-yoon, director general for global growth policy at the Ministry of SMEs and Startups, said the ministry is cooperating with the patent office and discussing response measures with other ministries. No measure was named. What is the plant's actual output, and whose figure is it? The capacity numbers from the visit are the company's own, and the two accounts of the same tour do not reconcile. One puts the Sejong plant at 38 filling and packaging lines and annual capacity of about 600 million units. Another puts it at 11 filling and packaging lines and about 890 million units a year. Both describe 2,500 to 3,000 items produced a month, 35 mixing tanks, and roughly 7,000 raw materials in use across the company. Production has been managed digitally in real time since 2023. The gap matters less as a fact about Kolmar than as a reminder of where these figures come from. Plant capacity in this industry is almost never disclosed in a filing. It is stated on a tour, and it is restated by whoever took the tour. Where did the export growth the fakes follow actually go? The ministry's own export release, published October 2, puts nine-month cosmetics exports at US$11.1 billion, up 31.1 percent, which is about 97 percent of the 2025 full-year total of US$11.42 billion. Skincare drove it, at US$8.72 billion and up 45.1 percent, while color cosmetics fell 3.6 percent to US$1.11 billion. Korean cosmetics exports grew 31.1% in the first nine months of 2026. The fastest growth was not in the largest markets. The United States took US$2.35 billion, up 40.6 percent, a 21.1 percent share against 10.8 percent in 2022. China took US$1.58 billion, up 0.4 percent, a 14.2 percent share against 46.7 percent in 2022. Behind them, the Netherlands rose 292.6 percent to US$369 million, the United Kingdom 179.3 percent to US$443 million, Canada 124.4 percent to US$285 million, and Japan 8.6 percent to US$889 million. Skincare shipments to the United States alone went from US$1.21 billion to US$1.80 billion. Every one of those destinations regulates a sunscreen differently from the country that made it. That is the second thing the plant visit surfaced, and it is the more structural one. Why is a Korean sunscreen a drug the moment it lands in the United States? In Korea, sunscreen is a functional cosmetic. Ultraviolet protection is one of the notified functional categories under the Cosmetics Act, cleared either by a simplified report when the product uses notified ingredients at specified concentrations, or by a full evaluation dossier when it does not. The product is a cosmetic throughout. In the United States it is not. The Food and Drug Administration regulates every product carrying a broad spectrum SPF claim as an over-the-counter drug, a medicine sold without a prescription under a monograph, which is the rulebook setting out which active ingredients, concentrations and label statements are permitted. A Kolmar Korea vice president, Lee Young-joo, raised exactly this at the plant, alongside the observation that country-specific ingredient and customs rules are where small brands lose time. The same tube is a cosmetic in Seoul and a drug in Dallas. Nothing in the jar changes at the border. The compliance object does. How rigid is the gate that drug status rests on? On June 9, 2026, the FDA added bemotrizinol to the list of permitted sunscreen active ingredients, at concentrations up to 6 percent. The final order followed a proposed order issued December 12, 2025 and a public comment period that closed January 26, 2026. DSM Nutritional Products requested the addition. One UV filter was added to the US monograph on June 9, 2026. FDA calls it the first new sunscreen active since the late 1990s. The agency described it as the first new sunscreen active ingredient since the late 1990s, and the first added under the streamlined process created by the CARES Act. That is one ingredient admitted in close to three decades. A Korean formulator's bench and the American monograph are not running on the same clock, and the distance between them is not a scientific disagreement so much as a procedural one. What does a counterfeit listing skip that an authentic shipment cannot? An authentic sunscreen entering the United States presents itself as a drug: a registered facility, a listed product, monograph-conforming actives, and a Drug Facts panel. That is the cost of the shelf, and it is paid before the first unit sells. A marketplace listing presents itself to nobody. It goes live, and the first review of it is a complaint. The counterfeits reported in October copied the package and, in the reported case of a Beauty of Joseon rice sunscreen sold through Amazon and TikTok Shop, the authenticity sticker and the retail price along with it. Industry accounts put detections and blocks of Korean cosmetics counterfeits on major overseas platforms at roughly 36,000 over the past two years, about double the level two years earlier. No agency is named as the source of that count, which makes it an order of magnitude rather than a statistic. The copy is cheaper for the obvious reason, and for a second one that gets less attention. It skips the formulation. It also skips the drug gate the authentic unit paid to clear. Why does the party that raised the problem hold no remedy? Kolmar Korea manufactures. The trademark on the copied sunscreen does not belong to it. Beauty of Joseon is operated by Goodai Global, which also runs TIRTIR, and the registered mark in each destination market sits with the brand owner. So does the drug position in the United States, because the entity that registers the facility and lists the product is the one that owns the label. The manufacturer carries the volume exposure. The trademark and the US drug filing sit with the brand owner. A trademark complaint runs on a registered mark and is made by the party that holds it. An ODM holds none on the products it fills. Its order book moves with the client's volume, and every instrument that touches the copy, from a platform takedown to a customs recordation to an invalidation action against a squatted mark, belongs to someone else. That asymmetry is why the complaint surfaced at a plant visit rather than in a brand's disclosure. What are the brands doing on their own? Goodai Global has expanded its in-house intellectual property team. APR has introduced AI-based monitoring of overseas platforms. Both are described in industry accounts rather than in disclosures, and neither substitutes for a registration in the destination market, because monitoring produces evidence and a registration produces standing. On the government side, what exists so far is coordination. The SME ministry described working with the patent office and talking to other ministries. Korean enforcement remains strongest where Korean agencies have jurisdiction, which is Korea's own border, and the revenue at issue is leaving on the other side of it. Where does this leave the three parties? For manufacturers. Capacity is not the binding constraint, and 38 lines against 11 is an argument about a press release. The binding constraint is that an ODM's revenue is exposed to a client's intellectual property position and the ODM holds no instrument to defend it. The lever it does hold is contractual: who pays for registration in each destination market, who monitors, and what happens to the order when a mark turns out to belong to somebody else. For brands and buyers. A Korean sunscreen presents two separate questions and they are answerable from documents before a purchase order. Who owns the mark in the market the goods are going to, and what is the product's status under that market's drug rules. A brand that can answer the first and not the second has a shelf problem rather than a legal one, and the reverse is also true. For regulators and investors. Korea clears the product as a cosmetic and polices copies at its own border. The United States admits it as a drug and moved its ingredient list once in nearly thirty years. Admission and enforcement are two different gates, run by two different agencies, on two different clocks. A genuine Korean sunscreen pays at both. A counterfeit presents itself at neither.

MARSHIQUE goes into 504 Ulta Beauty stores on November 1, after an October 18 start on Ulta.com. Ulta operated 1,534 stores in the United States at the close of its second quarter on August 1, 2026, so the launch covers roughly one door in three. The announcement calls the arrival the start of a category named K-Patch. Ulta's own K-Beauty filter already returns 65 patch products, and the retailer has carried wrinkle patches for years. What exactly launched, and in how many doors? The announcement, dated October 19, puts the online launch on October 18 and the in-store launch on November 1. It gives the store count twice and gives it differently: once as "500+ Ulta Beauty locations nationwide" and once as "504 Ulta Beauty stores nationwide." The assortment runs from $16 to $25 and covers patches for frown lines, smile lines, the forehead, the eye area and the neck, lifting patches aimed at facial contours, and the brand's eyelash serum. No individual product is named and no unit counts are given. Ulta ended its second quarter with 1,534 US stores. The MARSHIQUE rollout covers 504 of them. Ulta's own second-quarter results, for the thirteen weeks ended August 1, 2026, report 1,622 company-operated stores, 1,534 in the United States and 88 international, with net sales of US$3.04 billion, up 8.9 percent, and comparable sales up 3.8 percent. The announcement describes Ulta as the largest specialty beauty retailer in the United States and as having more than 1,500 stores. The store figure matches the filings. The superlative is the announcement's own characterization. What does Ulta's patch shelf already hold? Filtering Ulta's K-Beauty assortment to patches returns 65 products. The brands behind them include Hero Cosmetics, Rael, COSRX, ANUA, Peach Slices, MEDIHEAL, The Crème Shop, ROUND LAB, SOME BY MI, TIRTIR, SUNGBOON EDITOR, ma:nyo, VT Cosmetics and TONYMOLY. Prices on the listings run from $4.50 to $27.50. The function is narrower than the count suggests. Almost all of it is blemish, pore and dark spot work, built on hydrocolloid, the moisture-absorbing dressing material that gives a pimple patch its job, or on microdarts, dissolving micro-needles that carry ingredients below the surface. Ulta's own editorial guide to patches names Hero Cosmetics, Peace Out, Starface, e.l.f., COSRX and Rael. Every product on it treats a blemish. The guide does not mention wrinkle or lifting patches at all. I'm Charcoal All Over Blemish Patch by Tonymoly Where does the $16 to $25 band sit on that shelf? Against the Korean patch assortment it sits at the top. COSRX's original acne patch, 24 count, lists at $6.00. The most expensive Korean patch products on the filter are SUNGBOON EDITOR's collagen melting patch at $27.50 and MEDIHEAL's PDRN lifting pad at $26.40. MARSHIQUE tops out at $25.00, under the wrinkle patch incumbent at $30.00 and four times the Korean acne patch floor. Against the wrinkle patch assortment it sits underneath. Wrinkles Schminkles, which has fifteen products listed at Ulta, prices its forehead, eye, mouth, neck, chest and hand patches at $30.00 and its self-dissolving microneedle patches at $55.00. MARSHIQUE's ceiling of $25.00 clears neither shelf by accident. It is above the sticker and below the silicone. Is K-Patch a new category or an occupied one? Ulta already sells targeted wrinkle patches. Wrinkles Schminkles is the anchor, alongside M3 Naturals hypoallergenic forehead wrinkle patches and FOREO microneedling hyaluronic acid patches for the forehead. None of those brands is Korean. Ulta's K-Beauty patch filter returns 65 products. The wrinkle and lifting shelf next to it belongs to other brands. So the retailer runs two patch shelves that barely touch. One is Korean and treats blemishes. The other treats lines and is not Korean. What MARSHIQUE is entering is the overlap between them, and the overlap is empty enough to be worth naming. That is a real observation about the assortment. It is not the same claim as inventing a category, and the announcement is careful not to make the larger one. What does the announcement claim, and what does it leave out? It claims no first. It says the brand has positioned patches as a distinct beauty-care category in their own right, and that the goal is to establish K-Patch as a distinct beauty category that consumers around the world can discover. Both are statements of intent. The superlatives in the text attach to Ulta, not to MARSHIQUE. What it leaves out is more telling than what it asserts. The quotes carry no name and no title, attributed only to a MARSHIQUE representative. There is no parent company, no founding date, no revenue, no Korean retail footprint, no distribution term and no target. A launch announcement that names 504 stores and no executive is making a distribution statement rather than a corporate one. MARSHIQUE How has Ulta been adding Korean brands? By partnership and in batches. In July 2025 the retailer announced an exclusive arrangement with K-Beauty World covering eight brands, Chasin' Rabbits, I'm From, Mixsoon, Rom&nd, Neogen, Some By Mi, Sungboon Editor and Unleashia, for both stores and the website. The inflow behind that is large and still accelerating. Korean cosmetics shipments to the United States reached US$2.35 billion in the first nine months of 2026, up 40.6 percent, with skincare alone rising from US$1.21 billion to US$1.80 billion. The United States took 21.1 percent of Korea's cosmetics exports over that period, against 10.8 percent in 2022. A patch shelf 65 products deep is what that inflow looks like once it reaches a planogram. Why would a launch start at one door in three? Neither the retailer nor the brand has said how the 504 were chosen, and the announcement gives no criterion. Ulta opened fifteen stores and closed one in the quarter, so the fleet it is allocating against is stable rather than in flux. What the number establishes is a gap between the language and the shelf. "Nationwide" describes the geography of 504 stores accurately and describes their share of the chain not at all. For a brand, a third of the fleet is a position that has to be earned up rather than a position that has been won, and the second order, not the first, is where a launch like this is settled. What does naming a category buy that a listing does not? A product listing competes inside a filter that already exists, and at this retailer that filter returns 65 Korean results. A category name is a request for a separate filter. The request is granted by the retailer's taxonomy and by what shoppers type into a search box, and neither of those is controlled by the brand making the request. Until Ulta's navigation carries the term, K-Patch is positioning language on a product page that the retailer files somewhere else. The precedent for the attempt is the phrase it is built from. K-beauty became a shelf label because enough products arrived to need one, not because one brand proposed it. Where does this leave the three parties? For manufacturers. A wrinkle and lifting patch at $16 to $25 is a different object from a $6 hydrocolloid sticker. It carries more material per unit, more substrate engineering, and more claim substantiation, because a line-smoothing claim has to be supported in a way that a blemish cover does not. The patch format is becoming a place where formulation competence shows, which is a more durable position than a shape. For brands and buyers. The operative number in this announcement is 504 of 1,534. A buyer comparing two offers reads door count, price band and the shelf the product gets filed under, and a category name supplies none of the three. The second question worth asking is what happens at the reorder, because a partial-chain launch is a decision the retailer has deferred rather than made. For retail and capital. Ulta's Korean assortment has grown by partnership and by individual brand until the patch shelf alone runs 65 products deep. A new Korean entrant now competes with other Korean brands before it competes with anyone else. The constraint has moved from access to differentiation, and differentiation is the more expensive problem. The name is new. The shelf is not.

Galderma's October 14, 2026 agreement values ZO Skin Health at US$1.5 billion in cash against about US$330 million in net sales. Five weeks earlier, a sale process at around US$2 billion was reported. What changes hands is not a molecule: more than 40 products, all made in the United States, moving through more than 16,500 physician, medical spa and online accounts in more than 40 countries. The formula is not the asset. The account list is. What did Galderma actually sign on October 14? The agreement covers 100% of ZO Skin Health at an enterprise value of US$1.5 billion, all cash, subject to customary adjustments. Enterprise value is the price of the equity plus net debt, so it is what the buyer pays for the business rather than what the sellers receive for their shares. Galderma is funding it from existing cash reserves and bank financing. The sellers are shareholders including funds managed by Blackstone Tactical Opportunities and the Obagi family. Closing is expected in the fourth quarter of 2026 or early 2027, subject to regulatory approvals. The target is a physician-dispensed brand, meaning its products reach consumers through a licensed medical practice, a medical spa or an authorized provider's online store rather than through open retail. The release puts ZO at approximately US$330 million in net sales in the last twelve months as of June 2026, with more than 40 products manufactured in the US and more than 16,500 accounts across more than 40 countries. Galderma's own guidance on the arithmetic is specific. The deal is core EPS neutral in the first full year following closing, slightly dilutive to core EBITDA margin in 2027, and broadly comparable with the group average from 2028 onwards. The company also states it will increase commercial investment in the first year of ownership, with renewed growth expected from the second year. Galderma's October 14, 2026 agreement values ZO Skin Health at US$1.5 billion. Photo via Unsplash (free to use). Why did a US$2 billion process close at US$1.5 billion? On September 8, 2026, a sale process for ZO Skin Health at a valuation of around US$2 billion was reported, with Citigroup and Raymond James advising and the process at an early stage. The signed number is a quarter below that. No party has disclosed what moved between the two figures, and an early-stage valuation floated by people close to a process is not a price. The one public anchor is the acquirer's own language. Flemming Ørnskov, Galderma's chief executive, is quoted in the release saying the company sees "significant opportunities to reignite its growth through investment in innovation and commercial reach." Reignite is a verb used about a business that has cooled. Read alongside the commitment to a year of increased commercial investment before renewed growth arrives in the second year, the release describes an asset that needs work, not one running at full speed. Galderma's announcement dates the signing to October 14, 2026, with closing expected between Q4 2026 and Q1 2027. What does 4.5x sales mean next to the rest of 2026's beauty deals? US$1.5 billion against US$330 million in net sales is about 4.5 times sales. DC Advisory's count of 2026 beauty transactions puts median valuations at about 3 to 4 times revenue and 12.5 to 14.5 times EBITDA. On the revenue measure, this deal sits above the median rather than at it. An implied EBITDA multiple near 23 times has circulated in trade coverage. That figure rests on an assumed EBITDA margin of roughly 20% attributed to unnamed industry sources, and Galderma disclosed no earnings figure for ZO at all. There is one multiple in this transaction with a disclosed denominator, and it is the sales multiple. Anything built on an assumed margin is an estimate wearing the clothes of a fact. What is a physician-dispensed account, and why are there 16,500? ZO Skin Health was founded in 2007 by the dermatologist Zein Obagi and launched in department stores. It moved away from that shelf toward physicians, and in 2012 introduced physician affiliate and revenue-sharing programs that let doctors earn on patient purchases through physician-linked virtual stores. The company pairs protocol training and staff education with procedures such as lasers, chemical peels and microneedling, and controls distribution tightly, with some prescription products requiring a physician. That structure produces a number worth more than the formulations. Guidepoint Qsight found that nearly 40% of ZO customers at medical-aesthetics practices made a repeat purchase in 2025, which it described as the highest patient retention rate among the leading professional-grade skincare brands in its analysis. A repeat purchase in this channel is not a consumer rebuying a serum. It is a practice re-recommending a protocol, and a staff member re-explaining it. Sixteen thousand five hundred accounts is therefore not a distribution list. It is sixteen thousand five hundred clinical habits, each taught by someone. That is the part a competitor cannot copy by reformulating. A reception desk in a medical-style clinic lobby. ZO reaches consumers through more than 16,500 physician, medical spa and online accounts. Photo via Unsplash (free to use). What did Blackstone actually build between 2020 and 2026? Blackstone took a majority stake in ZO in 2020, when the business was projected to reach about US$140 million in annual sales. Shary Moalemzadeh of Blackstone is quoted in the release saying the company more than doubled its revenue during the partnership, and US$140 million to US$330 million is consistent with that. The trajectory inside those six years was not uniform. Cutera, ZO's former Japan distributor, reported about US$34 million in ZO product revenue in 2023, down from US$42.5 million in 2022, figures it put at 16% and 17% of its own total revenue in those years. That is one distributor in one market and not ZO's total Japan sales. Both things hold at once: a business that doubled across the holding period, and an acquirer budgeting a catch-up year on arrival. How does ZO sit next to Alastin without eating it? Galderma already owns Alastin, acquired in November 2021. Galderma disclosed no financial terms for that transaction, and the figure near US$470 million that circulates is a trade estimate rather than a disclosed number. At the time, Galderma described Alastin, citing Kline, as the fastest growing brand in the US professional skincare market in 2020, with sales compounding at 106% a year from 2016 to 2020. The release positions Alastin's peptide-based pre- and post-procedure line as complementary to ZO's retinol- and acid-based daily regimens, and a Galderma spokesperson has said the brands' distinct products and distribution limit cannibalization between them. Both nonetheless sell into the same room, to the same practice manager, through the same education model. Whether a practice runs two protocols or quietly picks one is settled by the two education teams after closing, not by the chemistry. ZO sells more than 40 products, all made in the United States, into the same treatment room as Galderma's Alastin. Photo via Unsplash (free to use). Kline puts the combined position at 19% of the US medical care provider skincare channel, an increase of 12.7 percentage points, in a US professional skincare market it sizes at US$2.6 billion in manufacturers' sales in 2025 and growing about 6% a year through 2030. Medical care providers are the largest distribution channel in that market. Is this the largest deal the professional channel has seen? The disclosed record is short. Allergan agreed in November 2012 to acquire SkinMedica, a physician-dispensed line, for US$350 million up-front plus US$25 million contingent on the acquired products reaching a specified level of net sales. Valeant agreed in March 2013 to acquire Obagi Medical Products at US$19.75 per share, valuing Obagi's common stock at approximately US$360 million. Obagi Medical is the company Zein Obagi founded in 1988 and whose name he no longer controls, which is why the brand he built afterward carries his initials instead. Against those, US$1.5 billion is a change of scale rather than a step up. The honest formulation is narrower than the headline one: this is the largest disclosed price in physician-dispensed skincare. A great many transactions in this channel, including Galderma's own purchase of Alastin, closed without terms being published, so the record of disclosed prices is not the record of deals. ZO is the largest announced physician-dispensed skincare deal in this comparison. The Alastin figure is a trade estimate. What happens to the shelf when injectables companies own it? Galderma reported 2025 net sales of US$5,207 million, up 17.7% at constant currency, and core EBITDA of US$1,211 million at a 23.3% margin. The split was Injectable Aesthetics at US$2,572 million, Dermatological Skincare at US$1,449 million and Therapeutic Dermatology at US$1,185 million. ZO's US$330 million adds about 6% to that group total and lands entirely in the smaller of the two aesthetics-facing segments. Dermatological Skincare was US$1,449 million of Galderma's FY2025 net sales. ZO's US$330 million in sales to June 2026 equals 6% of the group total. The ownership above it matters as much. L'Oréal doubled its holding in Galderma to 20%, a transaction expected to close by the end of the first quarter of 2026, following an initial investment in 2024. So the structure now reads in one line: an injectables-led group buys the skincare that sits beside the syringe, and a fifth of that group is held by the largest beauty company in the world. What does the same transaction tell three different readers? For manufacturers and contract developers, the premium here attached to the channel, not the chemistry. A supplier pitching a professional-channel brand is selling to a buyer whose scarce asset is an education team and a list of practices. Formulation capability is the entry condition, not the differentiator, and pricing a proposal as though the molecule carries the value misreads where this money went. For brands and buyers, the number to argue with is 40% repeat purchase at the practice. A brand that cannot produce a retention figure out of its own channel has no case for a multiple above the 3 to 4 times revenue median, whatever its clinical data says. Retention is the evidence that an account is a relationship rather than an order. For regulators and investors, the structure deserves the attention the price is getting. A revenue-sharing arrangement that pays a physician on patient purchases sits between clinical advice and a retail transaction, and that is a question several jurisdictions examine on its own terms. Consolidating the channel concentrates the question rather than answering it. The formula is portable. The account list is not. That is the whole price.

Not Your Mother's is now owned by Henkel, the German company behind Schwarzkopf and Persil. Henkel announced the deal on 9 March 2026 and completed it on 27 April 2026, buying the brand from the private equity firm Main Post Partners. Neither side disclosed the price. Barclays estimates about €800 million, or roughly $927 million, which is a little over four times the brand's annual sales. The price is an analyst estimate. Henkel and Main Post Partners did not disclose financial terms. Who owns Not Your Mother's today? Henkel has owned it since 27 April 2026. Henkel is a Düsseldorf-based group best known for adhesives and laundry brands such as Persil. Its hair portfolio includes Schwarzkopf, Got2b, DevaCurl, Alterna and SexyHair. Henkel describes hair as one of its core consumer categories, and Not Your Mother's adds a fast-growing US brand to it. Who founded Not Your Mother's, and who sold it? Rocky and Bethany Pagliarulo launched the brand in 2010 through DeMert Brands, the Tampa, Florida company they had bought in 2000. Main Post Partners, a San Francisco private equity firm, invested in 2019 and was the seller in 2026. Nelson Miranda, who became CEO in 2020, has since left. In August 2026 he was named CEO of the sun-care brand Vacation. How much did Henkel pay for Not Your Mother's? The companies agreed not to disclose financial terms. The $927 million figure is an estimate from the investment bank Barclays (about €800 million), reported by Beauty Independent. Henkel did disclose that the brand had about €190 million in sales in 2025, with double-digit growth and a strong gross margin. That puts the estimated price at a little over four times sales. Treat the price as an estimate until the companies confirm it. Why did Henkel want Not Your Mother's? There are three clear reasons. First, it is a young shopper's brand. In a Piper Sandler survey of 10,000 US teens, 11% named Not Your Mother's their top haircare pick, ahead of Amika (8%) and L'Oréal (7%). Second, it never stops launching. The brand releases 25 to 30 products a year, and its Curl Talk line makes up about 40% of sales. Products cost $7.99 to $11.99, and the brand sells in more than 40,000 US stores, including Ulta, Target, Walmart and CVS. Third, it grows in the biggest hair market. Henkel says the US is the largest hair market in the world, and this deal strengthens its position there. Curl Talk Defining Cream, from the line that makes up about 40% of the brand's sales. Image: Walmart. Clean Freak Dry Shampoo, the brand's 2011 breakout product. Image: Not Your Mother's. What does the deal mean for indie hair brands? This section is analysis, not reported fact. Mass-market hair can sell for a high multiple. A brand priced at about $8 reached roughly four times sales, so a low shelf price does not cap the exit. Buyers want growth. Barclays called the deal a departure for Henkel, which has mostly done value-type deals in the past. The hair category is busy. Color Wow sold to L'Oréal in a deal of about $1 billion, and the 2023 MAV Beauty deal was about $258 million. Key people move on. The former CEO is already leading another consumer brand. Related reading Not Your Mother's: The Brand That Sold for an Estimated $900M Lipstick Built K-Beauty's Empire. Shampoo Is Eating Its Lunch. Own the Factory, Lose the Customer: The Brutal Economics of $5.97 Shampoo Monday Sources Henkel press release, 9 March 2026 Henkel completion announcement, 27 April 2026 Main Post Partners announcement, 9 March 2026 Beauty Independent: Henkel acquires Not Your Mother’s Business of Fashion: Henkel acquires Not Your Mother’s Global Cosmetics News: Vacation appoints Nelson Miranda CEO

"I Don't Want My Mom's Stuff" — The Niche Hidden Behind a Rebellious Name In 2010, six unfamiliar bottles landed on the haircare shelves of 400 Walmart stores across the US. The brand was named Not Your Mother's. Surprisingly, it wasn't hatched by a sleek Silicon Valley startup. The operation behind it was DeMert Brands, an established company based in Tampa, Florida. Husband-and-wife duo Rocky and Bethany Pagliarulo had bought and revamped the firm in 2000, carving out a solid footprint in professional salon channels. Yet their claims to fame in the professional world had nothing to do with shampoos or conditioners. Their cash cow was an aerosol nail-polish dryer—a salon staple beloved by manicurists looking to speed up turnaround times. That product revealed DeMert’s true technical core: it wasn't deep hair-nutrition science, but rather masterclass aerosol filling technology designed to spray liquid in fine, perfectly even mists. That aerosol expertise would fuel the brand’s meteoric rise—and later, spark its darkest crisis. The Pagliarulos noticed a massive blind spot in the market. It wasn't about formula; it was about age and cultural identity. At the time, haircare aisles were dominated by practical, mature brands like Tresemmé and Head & Shoulders. The space targeting high school and college-aged women was virtually empty. Young women wanted salon-quality performance without breaking the bank, yet beauty conglomerates dismissed them as secondary consumers who simply borrowed their parents' products early. Rocky came up with the provocative name and concept. As Bethany later recalled, "Regardless of how much they loved their moms, this demographic was starving for an independent brand that reflected their own generation's style." By choosing a defiant negative phrase rather than a safe positive one, the brand drew a sharp line on the shelf. That cheeky pushback would take an unexpected turn 15 years later. ⓒNot Your Mother's Conquering Gen-Z Scalps with Salon-Grade Aerosol Tech The brand's breakout icon arrived a year after launch: Clean Freak Dry Shampoo (2011). Designed to absorb oil and sweat without water using fine rice and barley starches, it instantly revived limp hair. It was a lifesaver on busy mornings or skip-wash days—taking the exact aerosol mechanism used to quick-dry nail polish and repurposing it to tackle oily roots. The product lineup was brilliant in its simplicity. Collection names doubled as clear, immediate benefits: Curl Talk: Enhances natural curls and wave patterns. Beach Babe: Delivers effortless, ocean-tousled texture. Plump for Joy: Adds weightless, touchable volume. All Eyes On Me: Designed for high-impact, standout styling. For shoppers with zero patience to decode complex ingredient lists, the names served as effortless instruction manuals. Each line was also paired with its own signature scent—like Curl Talk's bright mix of citrus and fruity jasmine. ⓒNot Your Mother's Pricing sealed the deal. Today, most products hover between $7.99 and $10.99. In a market where prestige salon brands run $30 to $40, Not Your Mother's carved out a sweet spot: professional-grade results at drugstore prices. That balance gave the brand a ticket into both mass discount giants like Walmart and Target, as well as beauty specialty chains like Ulta Beauty. In February 2019, Main Post Partners—a San Francisco-based private equity firm—acquired a growth stake in DeMert Brands. While financial terms weren't disclosed, the buyout signaled an ultimate exit strategy. The Pagliarulos stayed on as co-founders, and by 2020, beauty industry veteran Nelson Miranda joined as CEO after 20 years at P&G and 7 years leading Revlon's North American prestige division. The Hidden Impurity & The Refusal to Recall On November 1, 2022, Valisure—an independent testing lab in Connecticut—filed a citizen petition with the FDA. After testing 148 batches across 34 dry shampoo brands, it dropped a bombshell: 70% of samples tested positive for Benzene, a known Class 1 human carcinogen linked to leukemia and blood cancers. Brand / Product Tested Initial Spray Benzene Concentration FDA Limit (Drug Residuals) Not Your Mother's Beach Babe 158 ppm 2 ppm Competitor Average 9 – 148 ppm 2 ppm Not Your Mother's Beach Babe Texturizing Dry Shampoo (Toasted Coconut) registered a staggering 158 ppm of benzene on initial blast—79 times the FDA's conditional limit for drug products, and the single highest reading in the entire study. Crucially, these numbers represented atmospheric concentrations in the sprayed air plume, not raw liquid composition inside the can. Given that dry shampoo is typically sprayed in small, enclosed bathrooms, air-concentration testing presented an immediate, tangible concern for consumers. Benzene was never an intentional ingredient. As P&G explained during its own earlier safety recall, the chemical entered as an impurity in the liquefied gas propellants used to blast product out of the can. The brand's sudden crisis didn't stem from its formula, but from the very aerosol container tech that built it. How the company handled the fallout set it apart from rivals: P&G & Unilever: Initiated broad, voluntary safety recalls in 2021 and 2022. DeMert Brands: Refused to pull products from shelves, maintaining that internal and supplier tests showed no detectable benzene. Class-action lawsuits quickly followed in New York and Florida federal courts seeking refunds and health monitoring, though ultimate court settlements remain undisclosed. For a brand built on clean, fresh vibes, the reputational hit was undeniable. $900 Million Win: 30 New Products a Year & Pure Agility It's worth correcting a common misconception: the brand's visual redesign and debut mass-media campaigns were not crisis-response measures. Both were rolled out in early 2022, nearly ten months before Valisure's petition. The real driver behind the company's continuous growth was much simpler: sheer speed. Not Your Mother's launches 25 to 30 new products annually. Instead of chasing fleeting micro-trends, it expands proven anchor lines. Case in point: the Curl Talk collection alone accounts for roughly 40% of total brand sales. Marketing shifted heavily toward creator ecosystems. In 2022, the brand teamed up with hair influencer Greta Wilson (1.4M followers) and deployed 127 micro-creators for a four-month TikTok campaign, driving 1.2 million views and 14,000 direct product clicks. Today, the company stands as the fastest-growing haircare brand on TikTok and holds the #2 spot in share of voice for hair routine content. Teamed up with hair influencer Greta Wilson, ⓒTikTok The results show in two striking numbers: Teen Favorite: In Piper Sandler’s Fall 2025 survey of 10,000 US teens, 11% voted Not Your Mother’s as their favorite haircare brand, beating out premium labels like Amika (8%) and L'Oréal (7%). Explosive Sales: Brand sales surged 40% in 2025—outpacing the overall US mass haircare category growth (4%) tenfold, even as teen spending contracted by 6% amid economic uncertainty. Unlike competitors chasing Direct-to-Consumer (D2C) online models, Not Your Mother's generated almost all revenue through physical retail across 40,485 doors—including Target, Walmart, Ulta Beauty, CVS, Walgreens, and Kroger. In October 2025, investment bank Raymond James was tapped to explore a sale. On March 9, 2026, German consumer goods giant Henkel officially announced an agreement to acquire the brand—citing ~€190 million in FY2025 sales, double-digit growth, and strong gross margins. Industry insiders estimated the deal at $927 million, and the acquisition closed on April 27, 2026. (That same month, Henkel also acquired prestige giant Olaplex for $1.4 billion, sweeping up leaders in both mass and prestige sectors). Not Your Mother's, ⓒHenkel From "Not Your Mother's" to "Passed Down by Mom" For years, the brand's mission statement stayed simple: "Self-expression is Self-love." That motto remained unchanged through shifts in executive leadership and ownership. Yet 15 years later, the audience has evolved. According to brand demographics, Millennials represent over a third of customer sales, Gen-Z accounts for 22%, and Gen-X fills out the rest. Millennials who used the products in college are now recommending them to their own daughters. A brand launched on a defiant "anti-mom" stance has come full circle to become a cross-generational staple—a rare feat in an industry where youth brands often fade with age. Not Your Mother's, ⓒHenkel While the brand highlights cruelty-free values by choosing not to sell in mainland China, its ethics carry nuanced caveats. China relaxed mandatory animal testing for imported general cosmetics in 2021, softening that distinction. Additionally, select formulas retain animal-derived ingredients, meaning the lineup isn't 100% vegan. Still, the growth trajectory remains remarkable. Expanding from 6 SKUs in 400 Walmarts to 86 products across 40,000 stores, the independent brand ultimately joined a €20.5B global titan. Yet through every corporate evolution, the bold name printed on the can stays the same—even as over a third of the shoppers reaching for it today are, ironically, mothers themselves.

China's customs administration moved Chinese-label review online in April 2026 and granted low-risk cosmetics shipments release on inspection. In July the drug regulator dropped ingredient registration codes and widened animal-testing exemptions. In October an industry association said roughly 15% of some French companies' cosmetics were sitting at Chinese customs and registration desks. Nothing in the published rulebook separates those two outcomes. What did China actually change for cosmetics importers in 2026? Two agencies control whether an imported cosmetic reaches a Chinese shelf. The General Administration of Customs, or GACC, clears the physical shipment. The National Medical Products Administration, or NMPA, controls the registration file — the dossier an importer must lodge before a product may be sold at all. Both moved in the same direction through 2026, and both moved toward the importer. GACC published a set of cross-border trade facilitation measures on April 28, 2026. For imported cosmetics the operative change was procedural rather than tariff-related: review of the Chinese-language label shifted from paper to online, and low-risk consignments became eligible for system-automated review, which the administration described as inspection and release on arrival. That built on an NMPA pilot opened on February 1, 2026 allowing electronic Chinese labels for a three-year period in Beijing, Shanghai, Zhejiang, Shandong, Guangdong and Chongqing, with Hainan duty-free cosmetics also eligible. The pilot keeps the substantive requirements in place — product name in Chinese, license number for special cosmetics, registrant name, net content, shelf life and safety warnings still have to reach the consumer — and moves the delivery mechanism to a QR code of at least nine millimeters square. The larger change came on July 29, 2026, when the NMPA issued Announcement No. 70 of 2026 on cosmetics licensing and registration, effective on the day it was published and overriding earlier NMPA documents where they conflict. It sets out seven simplifications. Ingredient registration codes and raw-material safety documents no longer have to be entered at filing; the applicant lists the ingredient manufacturer and keeps the safety data on file for inspection, and the NMPA will stop publishing the codes. Animal-testing exemptions widened to cover perm products, non-oxidative hair dyes, whitening products that work only by physical covering, and general cosmetics using new ingredients — children's cosmetics excluded, and conditional on the manufacturer holding a home-country GMP certificate and on a safety assessment carrying the argument. Similar-formula products under one brand and one holder may share microbiological, physicochemical, toxicity and human safety testing from a single representative product. Test data survives a move of production between China and overseas if registrant, name, formula and standards are substantively unchanged. Outside freckle and whitening, UV protection and hair-loss claims, companies may choose their own efficacy test methods. And a product launching in China first, or simultaneously, can file a China-first launch commitment instead of proving it already sells in its home market. That last provision is worth isolating. It removes the structural disadvantage faced by a brand that wants China as a launch market rather than an export afterthought. China's cosmetics regulators published four easing measures in 2026. The friction that drew attention arrived in the same year, on a different track. What is the French industry association actually claiming? Marc-Antoine Jamet, president of the French industry association Cosmetic Valley, told reporters on October 14, 2026 that some French cosmetics exports were facing delays clearing customs in China. The figure attached to the claim is roughly 15% of products from some member companies, held up at customs and registration procedures. China is France's second-largest cosmetics export market, worth about €1.8 billion a year against total French cosmetics exports of €22.4 billion. The attribution matters more than the number. The 15% is an estimate drawn from member companies, not a measurement published by any customs authority. Chinese authorities did not comment on the delays. No filing, notice or official statistic underwrites the claim, and the association has not published the method behind it. What exists is a trade body's characterization of what its members report. That is not a reason to dismiss it. Industry associations are usually the first to see a clearance problem, because they aggregate complaints that individual firms have commercial reasons not to make. It is a reason to hold the claim at the level it was made. Container cranes and stacked shipping containers at a busy port. Photo via Unsplash (free to use). Why does a cosmetics complaint point at a fashion law? France's anti-ultra-fast-fashion law took effect on September 1, 2026, imposing environment-related penalties on applicable textile products. China's Ministry of Commerce responded publicly within days, urging France to halt implementation and describing the law as discriminatory; France's foreign ministry rejected the discrimination characterization. European measures on low-value parcels sit alongside it in the same dispute. The association's reading is that the cosmetics delays follow from that quarrel. The sequence supports the reading without establishing it. A law takes effect on September 1, a government objects on September 3, and an exporters' body reports clearance friction on October 14. No Chinese authority has stated that cosmetics clearance reflects anything other than ordinary procedure, and no public document links the two. Suggestive ordering is not proof of mechanism. It is also worth noting what is not being alleged. Nobody has claimed a tariff, a quota, a ban, or a rule change aimed at French cosmetics. The complaint is about pace. Paris, where France's fast-fashion law took effect on September 1, 2026. Photo via Unsplash (free to use). How exposed is France, and how exposed is Korea? France sends about €1.8 billion of cosmetics to China out of €22.4 billion in total cosmetics exports, which puts China at roughly 8.0% of the national total. Korea's Ministry of Food and Drug Safety released first-half 2026 figures on July 3, 2026: about US$1.01 billion to China out of about US$7.0 billion overall, or 14.4%. Korea leans on the Chinese cosmetics market close to twice as hard as France does, measured as a share of national output. This is the inversion in the story. The exporter being slowed is the less concentrated of the two. China takes 8.0% of French cosmetics exports and 14.4% of Korea's. The country reporting delays is the one with less at stake in the market. Korea's share has fallen hard and fast from a much higher base, which is why 14.4% reads as diversification rather than dependence. The first half of 2026 was the period in which the United States consolidated its position as the largest market for Korean cosmetics, at about US$1.45 billion and 20.7% of the total, up 41.5% year over year. Japan took about US$0.58 billion, 8.3%, up 5.9%. Total exports rose 27.3% to a record first-half figure. A falling share of a growing total is a different thing from a retreat, and China's absolute decline was US$70 million on a base above a billion. Did Korea's China decline come from a gate or from demand? The category breakdown answers this more clearly than the headline number. Korean basic skincare to China fell 7.2%, from about US$830 million to US$770 million. Body cleansing products fell 25.0%, from about US$72 million to US$54 million. Color cosmetics were essentially flat, down 0.3%, from about US$117.9 million to US$117.5 million. Korean body cleansers to China fell 25.0% while color cosmetics held flat at -0.3%. Clearance friction does not sort itself by product category. A clearance or registration bottleneck does not produce that shape. Customs handles a consignment, not a category; a registration queue lengthens by dossier type, and color cosmetics in China carry at least as much filing burden as a cleanser. A gate that cut cleansers by a quarter while leaving color untouched would be a strange gate. Uneven category movement of this kind is what demand, channel mix and local competition look like. The contrast outside China sharpens it. Korean basic skincare to the United States rose 48.6% in the same half, from about US$740 million to US$1.10 billion, and personal cleansing to the US rose 36.4%. The same products, the same producers, the same half-year, moving in opposite directions in two markets. One analyst reading attributes part of the US surge to stock-building ahead of tariff increases; that is an interpretation offered by market analysts, not a figure anyone has established. So the available evidence does not show Korean cosmetics facing the clearance problem the French association describes. No Korean industry body has reported one, and the export data does not carry its fingerprint. The honest position is that Korea's China decline and France's China delays are two different phenomena that happen to involve the same border. What does the registration file actually control? An imported cosmetic cannot be sold in China until its dossier is accepted. General cosmetics are filed; special cosmetics — including sunscreens, whitening products and hair dyes — require a license, which is a substantive approval rather than a notification. The dossier is where the formula, the safety assessment, the efficacy evidence and the labeling all converge, and it is reviewed by people applying standards that leave room for judgment. This is the part of market access that behaves least like a rule and most like a queue. A tariff line — the code in a customs schedule that fixes the duty on a given class of goods — is a published number that an importer can read, forecast and contest. The time a dossier spends in review is none of those things. It is not published, it is not uniform, and a delay inside it is indistinguishable from ordinary diligence. That asymmetry is the reason a registration queue is a usable instrument and a difficult accusation. There is nothing for the affected exporter to point at. Cosmetics only reach Chinese shelves once the registration file is accepted. Photo via Unsplash (free to use). Which lever is written down, and which is not? Everything China did for cosmetics importers in 2026 arrived as a published document with a number and a date. GACC's facilitation package is dated April 28. The NMPA's registration overhaul is Announcement No. 70 of 2026, effective July 29. The electronic-label pilot has a start date, a province list and a duration. Each is citable, and each can be reversed only by another document of the same kind. What the French association describes has no document. There is no notice instituting it, no effective date, no scope and no stated end. It cannot be cited, which also means it cannot be formally challenged, appealed or made the subject of a trade complaint in the way a published measure can. Both tracks currently point Korea's way. The registration burden on Korean exporters fell in July, the label process got faster in April, and no Korean clearance problem has been reported. That is an accurate description of the present and not a structural protection. The measures that helped were discretionary when they were granted, and discretion does not change character because it has been exercised favorably. What does this leave for the rest of the industry? For manufacturers, the registration file has become partly a product of the plant rather than the laboratory. An animal-testing exemption that is conditional on a home-country GMP certificate turns that certificate into an export asset with a measurable value, and makes the choice of production site a regulatory decision rather than a cost decision. Data-sharing across similar formulas rewards portfolio structure over one-off reformulation. For brands and buyers, a market whose entry cost falls by notice can see it rise the same way. Fourteen percent of national output in a single market is a concentration whether or not anything is currently going wrong in it, and the relevant comparison is not Korea against its own past but Korea against the exporter now reporting friction. France is at eight. For regulators and investors, the French case describes a trade measure that is hard to price. It leaves no mark in a tariff schedule, the acting government has not confirmed it, and the affected industry can only estimate its size. Published rules can be argued with. Queues cannot.

Since 10 October 2026, the EU has capped a chemical called PFHxA at 25 ppb in every cosmetic product sold on its market. PFHxA belongs to the PFAS family, often called "forever chemicals". A second cap of 1,000 ppb covers related chemicals that can break down into PFHxA. The rule never asks whether the chemical was added on purpose, and that is the catch: a formula sheet cannot answer it. What decides the outcome is the impurity statement from the raw material supplier, and most suppliers were never asked for numbers this precise. The EU rule sets two limits and four start dates. Cosmetics are covered from 10 October 2026, and nothing in the rule asks whether the chemical was added on purpose. What exactly changed on 10 October 2026? The EU adopted Commission Regulation 2024/2462 on 19 September 2024, and it took effect on 10 October 2024. It added a new rule, known as entry 79, to REACH, the EU's main chemicals law. The rule covers PFHxA (a PFAS chemical with a six-carbon chain), its salts, and a defined group of related chemicals that can break down into PFHxA. The Berlaymont building in Brussels, headquarters of the European Commission, which adopted Regulation (EU) 2024/2462. Photo: Trougnouf (Benoit Brummer), CC BY 4.0, via Wikimedia Commons. The rule says these substances may not be sold or used at a concentration of 25 ppb or more (PFHxA and its salts combined), or 1,000 ppb or more (the related chemicals combined). The amount is measured in the finished material itself, not the whole packed product. A ppb is one part in a billion. In a 50 ml jar of cream, 25 ppb is about 1.25 micrograms. The rule covers five product groups: clothing textiles, leather, furs and hides for the general public (and their accessories); footwear; paper and cardboard that touches food; mixtures sold to the general public; and cosmetics, as defined in EU cosmetics law (Regulation (EC) No 1223/2009). The same entry has other start dates too. Firefighting foams for training and public fire services started on 10 April 2026. Non-clothing textiles follow on 10 October 2027, and civil aviation foams on 10 October 2029. Cosmetics got a two-year grace period, which ended this month. Why does it matter that the rule ignores intent? Most chemical rules are about a choice. A banned-ingredient list asks what the maker decided to put in, and the answer is on the formula sheet. Entry 79 is about a measurement instead. It sets a concentration limit and stops there. It makes no difference whether the chemical was added on purpose, arrived as a contaminant in a pigment, or formed while the batch sat in a warehouse. The rule decides which chemicals count by their molecular shape, not by what they do in the product. A "PFHxA-related substance" is any chemical that could break down into PFHxA because of its structure. In practice, that means chemicals built around a chain of five or six fully fluorinated carbon atoms (written C5F11- or C6F13-). A few specific forms are carved out, including C6F14 and C6F13-C(=O)OH. So whether a material is covered depends on its chemical skeleton, not on its job in the product. The closest neighbouring rule works differently. France's Law No. 2025-188 was adopted by the National Assembly on 20 February 2025 and published a week later. From 1 January 2026 it bans making, importing and selling cosmetics with intentionally added PFAS, with an exemption for products below a residue limit that a later decree will set. So the French rule turns on intent and allows a small leftover amount. The EU rule turns on a number, with no intent test and no allowance for unavoidable traces. How can PFHxA end up in a formula nobody added it to? PFHxA is not a cosmetic ingredient. It does nothing useful in a cream and never appears on an ingredient list under its own name. It reaches a finished product in one of two ways: as an impurity carried in a raw material, or as a breakdown product of a larger fluorinated chemical that was added deliberately. Powders, foundations and other long-wear formats are where fluorinated materials tend to be used. Photo: Shixart1985, CC BY 2.0, via Wikimedia Commons. Some fluorinated materials do appear on cosmetic ingredient lists, and the list is short. It includes PTFE (the non-stick coating chemical), perfluorodecalin, perfluorohexane and a handful of silicone and ether compounds with similarly long names. They help products last longer, resist water and hold colour, so they are mostly found in powders, mascaras, foundations and long-wear treatments. Only some of them fall inside the structural boundary the rule draws, and the name on the label is a weak guide to which ones. That is why checking the ingredient list is the wrong first step. A product with none of those names can still carry more than 25 ppb, because the residue can travel in the pigment, the silicone or a processing aid rather than in the functional ingredient. A product that does contain one of them can still sit well under the limit. You cannot predict either result from the formula alone. A consignment cleared into the EU on 9 October 2026 is exempt. Identical stock in a Korean warehouse that day is not. What does "measured in the finished material" mean for a cosmetic? For a layered product, the rule looks at the smallest part that can be separated on its own, such as a coating measured apart from what it sits on. For a cosmetic, that part is the formula itself: the cream, the pressed powder or the mascara. The weight of the bottle, the cap and the carton is not counted. That cuts two ways. You cannot dilute a result by spreading it across the whole packed unit, which some exporters hoped for. But the limit applies to the finished batch, not to each incoming material, so a pigment with a high residue can still pass once it is mixed in at a small share. The maths is doable, but it has to be done material by material, with a number for each one, and redone whenever a supplier changes. The rule also has no "treat it as zero" threshold for very low test results. The explanatory notes at the start of the law say that testing methods are available and reliable, but they do not create a safe harbour in the rule itself. There is no clause for results below the limit of quantitation (the lowest amount a test can reliably measure), and no exemption for unavoidable traces. A liquid chromatography and mass spectrometry setup of the kind used to measure trace substances in a material. Photo: US government, public domain, via Wikimedia Commons. Which stock is covered, and which is exempt? Paragraph 7 is the transition rule, and it is one sentence: the limits do not apply to articles and mixtures that were already placed on the market before 10 October 2026. Paragraph 8 does the same job for the 2027 textile date, but covers articles only. Everything turns on what "placed on the market" means. Under REACH, it means supplying a product or making it available to someone else, whether paid or free, and importing counts as placing on the market. So the key event is customs clearance into the EU. A consignment cleared on 9 October 2026 was already on the market and stays outside the restriction for the rest of its shelf life. Identical product sitting in a Korean warehouse that same day had not been placed on the EU market, and every unit of it will be placed on the market after the cut-off. Container cranes at the Port of Antwerp. For an importer, customs clearance into the Union is the placing-on-the-market event. Photo: Trougnouf, CC BY 4.0, via Wikimedia Commons. Recital 25 puts the burden of proof where you would expect: the restriction should not apply where the supplier can show the product was placed on the market earlier. "Show" is the key word. Stock that crossed in time is exempt only if there is a record proving it crossed in time. Why is that exemption worth far less to an exporter than to a distributor? For an EU distributor holding stock, paragraph 7 is a lasting asset. The stock in the warehouse was placed on the market before the date, so it stays outside the restriction and can be sold down at its own pace. The problem has a limited size and an end date. For a manufacturer outside the EU, paragraph 7 is almost worthless. Nothing in the home warehouse was ever placed on the EU market. Every future shipment counts as a new placing and is judged against the limit at the moment it clears customs. An importer can bank this transition relief, but the exporter never holds it. That is why the two sides of the same supply contract read the same paragraph so differently. The practical cost comes from that gap, and it is not a reformulation cost. Removing a named ingredient is a project with a clear scope. Proving that an incoming lot of titanium dioxide, a silicone elastomer or a wax carries less than 25 ppb of a six-carbon acid is different. It is a paperwork problem spread across every material in the recipe, and suppliers have rarely been asked that question at that level of detail. The real constraint is data from upstream suppliers, and reformulating does not fix it. What does Korea's own PFAS rule cover, and what does it leave open? Korea treats these chemicals as banned cosmetic ingredients. In May 2024 the Ministry of Food and Drug Safety (MFDS) updated its testing guide for banned ingredients to add one method that tests for 12 PFAS at once, the first time the group appeared in that guide. No numerical limit comes with it, because a ban does not need one: the permitted amount is none, and the question is whether the substance was used. That is a coherent rule, and it asks a different question from the EU one. A manufacturer who can certify that no PFAS were used has fully satisfied the Korean rule, but has produced nothing that answers entry 79, which asks what is in the material rather than what went into it. Two documents, two questions, and the first does not answer the second. Whether Korean cosmetics actually carry PFHxA above the EU limits is not known from public data. No survey of PFHxA in Korean products or raw materials has been published. The screening study most often cited when the guide was revised was Canadian and measured total fluorine, not PFHxA. It found fluorine in 52 per cent of the cosmetics tested, including 82 per cent of waterproof mascaras and 63 per cent of foundations. Total fluorine shows that the wider chemical family may be present, but it is not a measurement of the restricted substance. What we can see here is how the two rules are built, not the result of tests that have not been done. A Korean certificate saying no PFAS were used fully answers Seoul's question, but does not answer Brussels' question at all. How long did this take, and what comes next? Germany submitted the restriction proposal to the European Chemicals Agency in December 2019. The agency's risk committee backed a broad restriction in June 2021, and its socio-economic committee agreed in December 2021. The European Commission adopted the regulation in September 2024, it took effect that October, and cosmetics got two more years. From proposal to enforceable number took close to seven years. A much broader EU-wide PFAS restriction is moving through the same process and is now past its midpoint. The risk committee published its final opinion, and the socio-economic committee a draft opinion, in March 2026, with public consultation running to 25 May 2026. The socio-economic committee is expected to adopt its final opinion by the end of 2026. After that the Commission prepares a proposal for the REACH Committee, and the European Parliament and Council review it with a power of veto but no further required consultation. The lists of exemptions are the part worth reading. The risk committee supported exemptions for protective equipment and related waterproofing agents, and rejected a proposed exemption for fully degradable PFAS groups because of a lack of evidence. The socio-economic committee recommended time-limited exemptions for eight more sectors: printing, sealing, mechanical applications, other medical uses, military, explosives, technical textiles and broader industrial uses. Cosmetics appears on neither list. Where does this leave suppliers, brands and buyers? For the raw material supplier, an impurity profile stops being internal know-how and becomes a product specification. A pigment maker that can put a PFHxA number on a certificate of analysis (a lab report for a specific batch) is selling something that a maker without one is not, and that difference now has a price. For the brand and its contract manufacturer (an ODM: a company that develops and makes a formula that the client sells under its own name), the key document changes. The formula sheet used to prove compliance under an ingredient-based rule. Under a concentration-based rule it proves very little, and the file of incoming-material test results takes its place. Those are handled by different departments, with different budgets and different levels of seniority. For buyers and investors, the due-diligence question changes in the same way. Asking whether an ingredient list is clean was a fair test while the rules were about ingredients. Against a number measured in the finished material, the useful question is narrower and harder to answer well: can this supplier produce a figure, for this material, from this lot? Seven years of process ended in a limit that nobody puts in the jar on purpose. The formula was never the control point. The certificate of analysis is.

South Korea entered Colliers' ranking of origin markets for new Central London store requirements for the first time in January 2026, in third place behind the United States and the United Arab Emirates. The number of requirements that earned it that place was four. Landlords now issue press releases naming K-beauty tenants, and leasing agents log Korean demand as a line of its own. The category is real. Its scale, measured in signed requirements, is smaller than the announcements make it sound. Korea was absent from Colliers' London origin list in January 2025. In January 2026 it ranked third, on four requirements. What did Colliers actually count in January 2026? The Colliers demand tracker records requirements — a retailer's stated brief for space in a given market, logged by the agency before any lease is signed. A requirement is an intention, not a transaction. In January 2026 the tracker held 136 requirements across Central London, against 127 in January 2025. Inside that total, new entrants — operators with no existing Central London store — rose from 12 to 25, the 108 percent increase that supplied the headline. The origin ranking sits within that new-entrant figure. The United States led with six requirements, the United Arab Emirates followed with five, and South Korea came third with four. Colliers' co-head of London retail described January as the first month South Korea had appeared on the firm's top origin list, and attributed the entry to the run of K-beauty brands taking space in London. The tracker named PURESEOUL, Moida and Skin Cupid among the operators behind it. Four is a small number, and the comparison inside the same month makes that plain. Food and beverage operators accounted for 57 of the 136 requirements. Leisure operators accounted for 27, fashion and accessories for 13. K-beauty's arrival on the origin list is a threshold event in a ranking that turns on single-digit counts, not a shift in the composition of London demand. Why are West End landlords announcing beauty tenants by name? Two London estate owners have published standalone press releases for K-beauty lettings. Soho Estates announced in April 2025 that Skin Cupid would take 3,003 square feet at Ilona Rose House, 111–119 Charing Cross Road, for the retailer's first permanent store. A director at Soho Estates said in that announcement that Skin Cupid's arrival was "a great example of the kind of curated retail that helps keep Soho vibrant and relevant." The letting followed a Skin Cupid pop-up at The Outernet in December 2024. Shaftesbury Capital announced in May 2025 that PURESEOUL would open a 3,000 square foot flagship across two floors at 11–12 Carnaby Street that June. The release carried a comment from the company's director of retail and restaurant leasing on the retailer's choice of Carnaby Street for its largest store, and one from PURESEOUL's chief executive. A landlord press release is a leasing signal, not a financial one. Estate owners publish them for tenants they expect to pull footfall across a whole estate rather than fill one unit, because the announcement itself becomes a line in the pitch to the next tenant. That is what separates these two lettings from the rest of the eighteen Korea-linked leases signed in Britain in the nine months to September 2026, none of which an owner announced. The two documented London K-beauty flagships are both almost exactly 3,000 square feet. The Berlin flagship is 150 square metres. Who actually signs a K-beauty lease in Britain? Not, in most cases, a Korean company. PURESEOUL was founded in 2019 by Leslie Tang, Gracie Tullio and Wing-Sze Tang, and runs as a British retailer with a London office and staff in Seoul. Its co-founder has described it as a British-born start-up with no parent company behind it. It reached 15 UK stores by May 2026, when it opened in Bath, and has said it intends to double that estate by the end of 2026, with roughly five stores under construction and three further leases signed. Those expansion figures are the company's own. Skin Cupid was founded by Melody Yuan and trades as an Asian beauty retailer rather than a single-brand outlet. Moida, which trades as a K-beauty chain, opened at Westfield White City in February 2025, Manchester Arndale in January 2026, Bullring in Birmingham in April 2026 and Battersea Power Station in June 2026. The distinction matters for anyone reading this as a Korean export story. The party taking the lease, paying the rent and carrying the covenant is a European multi-brand retailer. A brand stocked on Carnaby Street has not taken a Carnaby Street lease, and does not hold the option to renew one. How much space has the category taken? An agency count of Korea-linked lettings in Britain put 18 K-beauty leases in the nine months to September 2026, covering roughly 55,000 square feet, or about 5,100 square metres, across major retail districts. Those are the agency's own figures rather than a public register. They divide to about 3,000 square feet a store, which matches the two documented Soho lettings almost exactly, and describes a format closer to a specialist chain unit than to a department store concession. The clustering is the part leasing agents emphasise. Moida, PURESEOUL and Skin Cupid all trade within a short walk of Charing Cross Road, alongside Korean food operators including Bunsik, Oseyo and Seoul Plaza. A researcher at Cushman & Wakefield has characterised the pattern as a structural feature of the European retail market rather than a passing one, on the argument that adjacent Korean beauty and food outlets extend dwell time and generate repeat visits. Dwell time is the argument that converts a small tenant into a desirable one. It is also the argument an estate owner makes about any cluster it has already assembled, and it is untested for this category over a full lease cycle. The first of these London stores opened in 2025. What does the German build-out look like at street level? Moida took roughly 1,200 square metres at Spitalerstraße 10 in Hamburg, in the Semperhaus building, in an expansion reported in May 2026. That is the largest single K-beauty unit documented in Europe and roughly four times the size of the London flagships. Berlin is a different scale. HGHI Holding, which owns the Mall of Berlin, announced in July 2026 that Yeppo & Soonsoo would open a flagship there in a 150 square metre unit. The owner and managing director of HGHI framed the arrival of brands of that kind as evidence of the centre's pull, and set it inside a wider programme of restructuring space and adding international names. The Mall of Berlin draws around 22 million visitors a year. A 150 square metre unit inside a centre of that size is a test, not an anchor. German retail commentary circulating in Korea has gone further, describing K-beauty as having displaced carmakers and electronics brands as a source of demand for prime German retail space since 2025. That comparison does not appear in any published brokerage report this article was able to obtain, and it is not relied on here. Shaftesbury Capital publicised a K-beauty flagship in 2025. Its half-year results to 30 June 2026 name Sephora, Matière Première and INITIO, and no Korean retailer at all. Where does K-beauty sit in a landlord's own accounts? Shaftesbury Capital's half-year results to 30 June 2026 record 226 leasing transactions representing £23.2 million of contracted rent, 5 percent ahead of the December 2025 estimated rental value and 18 percent ahead of previous passing rents. At period end, 2.6 percent of estimated rental value was available to let. The beauty tenants those results name are Matière Première, which opened its first UK store, INITIO Parfums Privés, which opened its first standalone UK boutique in the Market Building, and Sephora, which launched its new boutique format and first West End store on the estate over the summer. K-beauty appears as no category, and no Korean retailer is named — in the same portfolio whose leasing team put out a press release for PURESEOUL the year before. That gap is the honest measure of where the category stands in European retail property. It is large enough to be worth announcing and too small to be worth reporting. Estimated rental value, the figure landlords use to describe what a unit should earn at market terms, is where a tenant category registers once it starts setting rents. K-beauty has not reached that line. Is this K-beauty demand, or London supply? Colliers' co-head of London retail set out the market condition alongside the origin ranking: appetite for London space is strong, supply in prime locations is low, and there is competitive tension for the best units. Shaftesbury Capital's 2.6 percent availability is the same condition stated as a portfolio number. In a market with that little slack, a landlord's willingness to court an unfamiliar category is not primarily a judgement about the category. It is a function of how many alternatives are bidding for the same unit and how much the owner needs a name that reads as new. The full-year 2025 tracker showed Central London requirements up 37.9 percent on 2024, with leisure operators up 60.1 percent and fashion and accessories up 53.6 percent. K-beauty entered a market that was already bidding itself up, and its four January requirements were counted against that backdrop. The corollary holds in the other direction. A category that gets its pick of units in a tight market has not proved it can hold them in a loose one. What do the export numbers underneath the leases show? Korean cosmetics exports reached $11.4 billion in 2025, the highest annual total recorded by the Ministry of Food and Drug Safety. The three largest destinations were the United States at $2.2 billion, China at $2 billion and Japan at $1.1 billion. Europe did not appear among them. Europe's position changed in the first half of 2026. Korea Customs Service figures put shipments to 58 European countries at $1.596 billion against $1.570 billion to the United States and Canada, the first half-year in which Europe outranked North America as a destination for Korean cosmetics. The margin was $26 million, under 2 percent of either figure. That is the same shape as the leasing data. Europe passed North America; it did not pull away from it. A category that leads by two percent on exports and holds third place on four London requirements is at the point where the direction is clear and the position is not yet secure. Both numbers reverse on a single bad quarter. What does the category look like from three sides? For a landlord, a K-beauty letting is a 3,000 square foot bet on dwell time in a market with almost nothing left to let. The downside is ordinary covenant risk on a small unit. The upside is a cluster that prices the next letting. That trade favours the owner at current availability and stops favouring it the moment availability widens. For the European retailers signing these leases, the category is the business rather than a line inside it. Doubling a fifteen-store estate inside a year is a retail rollout with retail rollout economics: rent, staffing, and the question of what like-for-like sales do in each catchment once the novelty premium is spent. These operators carry the property risk that the Korean brands on their shelves do not. For Korean suppliers, the leases sit on someone else's balance sheet. Shelf space in Soho, Hamburg and Leipziger Platz is distribution won without capital committed, and distribution that ends on a buyer's decision rather than a lease break. The brands with the most European visibility currently hold the least European property, and the least say over what happens to the shelf. The announcements are running ahead of the accounts. That is normal at this stage of a category. It is also the reason to read the leasing trackers rather than the press releases.

In August 2026, Korean shampoo left the country at $6.00 a kilogram, up from $5.00 a year earlier. Korean lip makeup left at $55.10 a kilogram, down from $62.30. Both categories shipped more volume than they had the year before. Only one of them was paid more for it. The export line K-beauty built its reputation on is now growing by charging less, and the line nobody wrote about is growing by charging more. What do the customs figures actually say? Hair products move under HS 3305, the tariff line covering shampoo, conditioner, styling and scalp preparations. A tariff line is the customs classification an exporter declares at the border, and it is the unit in which trade statistics are kept. Exports under it reached $403.25 million in the first eight months of 2026, up 33.7% on the same period a year earlier. Shampoo alone, HS 330510, accounted for $155.12 million of that, or 38.5% of the line, up 38.3%. Full-year shampoo exports in 2025 were $178.07 million, so eight months of this year reached 87% of the whole of last year. Lip makeup moves under HS 330410. In August it shipped $41.97 million, up 4.8% from $40.05 million. Which category is growing on price, and which on volume? In August, shampoo exports rose 35.7% in value, from $15.75 million to $21.37 million. Volume rose 12.8%, from 3,149.1 tonnes to 3,551.5 tonnes. The average price rose from $5.00 to $6.00 a kilogram, up 20.3%. Most of the growth was price. Lip makeup rose 4.8% in value over the same month. Volume rose 18.4%, from 642.9 tonnes to 761.4 tonnes. The average price fell from $62.30 to $55.10 a kilogram, down 11.5%. The category shipped 18% more product for 5% more money. In August 2026 shampoo exports gained 20.3% in price per kilogram. Lip makeup lost 11.5%, and made up the difference in volume. How does hair care’s record compare with its own history? Hair product exports were $416.51 million in 2021, then fell to $341.86 million in 2022, a drop of 17.9%. They recovered to $358.22 million in 2023 and $413.08 million in 2024, and reached $478.17 million in 2025, up 15.7% and a record. A record in 2025 therefore sits on a line that spent three years climbing out of a single bad year. What is different about the current run is the rate rather than the level. Exports reached $232.72 million in the first five months of 2026 against $178.15 million a year earlier, up 30.6%, and $403.25 million through August, up 33.7%. Neither of those is a recovery number. On the comparison with lip makeup, one caution belongs in the open. The customs series publishes lip makeup by month rather than as a running total for the same window, so the point at which the two lines crossed cannot be dated from the public figures. Lip makeup shipped $53.8 million in April and $41.97 million in August, a monthly range that sits below hair care’s pace. A range is not a crossing date. What the published figures do support is the direction of each line and the price behaviour underneath it. Hair product exports took until 2024 to pass their 2021 level. The 2025 record is the first year clear of that recovery. Why do two official figures for the same category disagree? The customs line puts 2025 hair product exports at $478.17 million. The Ministry of Food and Drug Safety’s 2025 production and export statistics put hair products at $590 million, 5.1% of $11.4 billion in total cosmetics exports. The gap is $112 million on a category of that size. Neither figure is wrong. One counts a tariff line; the other counts a product type as defined under cosmetics law, and the two sets do not hold the same items. Anyone sizing the category picks a number more than a hundred million dollars apart depending on which register they read. The same register problem blocks the lip comparison entirely on the regulatory side. The ministry’s statistics group lip products inside colour cosmetics, which it puts at $1.51 billion, or 13.2% of exports, alongside eye and face products. Basic skincare is 74.7%, at $8.53 billion. Lip makeup exists as a separate number only in the customs series. Where is the shampoo money coming from? Through August, the United States took $35.11 million of Korean shampoo exports, up 84.2%, and has been the largest single market for six consecutive months. China took $23.05 million, down 1.3%. Greater China, meaning China, Taiwan and Hong Kong together, took $39.84 million, up 5.5%, with its share of shampoo exports falling from 35% across 2025 to 26% in the first eight months of this year. The United States took $35.11 million of Korean shampoo exports through August, up 84.2%. China alone fell 1.3%. The August detail shows where the price came from. US value rose 30.6% to $4.503 million on volume up 4.7%, with the average rising from $5.50 to $6.90 a kilogram, up 24.7%. China’s value fell 12.9% to $2.787 million while its average rose from $3.40 to $4.90 a kilogram, up 43.9%. Fewer shipments, higher prices, in both directions. The highest average among the ten largest destinations in August was the Netherlands, at $25.80 a kilogram on $773,000 of shipments, more than four times the category average. Canada took $1.12 million at $6.20 a kilogram and Poland $1.117 million at $6.40. Brazil rose 179.0%, from $291,000 to $812,000. What is happening to lip makeup’s best markets? In August the United States remained the largest destination for lip makeup, but its value fell 8.1% and its average price fell from $51.70 to $47.10 a kilogram. Japan’s value and average both fell, the average from $73.10 to $64.20. China’s value fell from $2.467 million to $2.045 million while its average edged up from $69.70 to $71.80. Vietnam’s value fell with its average down from $80.80 to $63.70. Growth came from cheaper ground. India’s value rose 77.3%, from $810,000 to $1.436 million, with the average falling from $67.50 to $44.70 a kilogram, a third off the price. The exception runs the other way: the United Kingdom went from $918,000 to $2.249 million with its average rising 13.4% to $111.90, the highest of the major markets. Türkiye took $1.717 million at $87.20. The ranking had already moved earlier in the year. In April, lip makeup exports totalled $53.8 million, up 5.1%, with Japan at $17.0 million and up 62.4%, overtaking the United States at $13.9 million and down 7.8%. Is the domestic market feeding the export line? Hair care has been the fastest-growing category at CJ Olive Young, with annual growth above 70%. In the first two months of 2026 its hair product sales rose 48% and styling sales rose 90%. Nine in ten users of its scalp diagnostic service are international tourists. Those figures are the retailer’s own. The tourist channel has changed scale underneath them. 18.5% of foreign visitors to Seoul used a hair salon or beauty service in 2025, against 3.6% in 2019, a rise of 14.9 percentage points, according to the Seoul Tourism Foundation’s survey. Capital has followed the same line. In September 2025 Blackstone took a controlling stake of more than 70% in Juno Hair, a salon chain of more than 180 locations, for over 500 billion won — about $372 million at the rate of 1,345.1 won to the dollar at which the won closed on 13 October 2026, the rate used for every conversion in this article. Grand View Research projects the Korean hair care market to grow from $3.8 billion in 2024 to $6.1 billion by 2030, a compound annual rate of 8.4%. CJ Olive Young Whose numbers are these, and what do they actually claim? Cosmax reports hair care revenue up about 65% in the first half of 2026 and 37 patent applications in hair care over the past three years. Those are applications rather than grants, and the figures are the company’s own. The work behind them is specific. The company has completed a patent application for a model that estimates alopecia areata risk without taking a biological sample, trained on about 22 million national health checkup records from Korea and Japan across 33 variables including blood pressure, liver enzymes, and demographic and socioeconomic indicators. It has analysed scalp target lipids in 387 subjects of East Asian, European and African descent and grouped scalps into three types, with a biomarker panel by ancestry planned. With Seoul National University it developed CORELINK-S, a material the company says improves the tensile strength of damaged hair by more than 120%. It received an IFSCC award in 2025 for organoid work — laboratory-grown tissue models used in place of human or animal testing — on stress-related greying. Separately, Cosmax recorded triple-digit hair care export growth in each of the three years from 2023 to 2025, and Kolmar Korea expanded its hair care research headcount by 40% last year. A scalp claim that survives review in three jurisdictions is worth more per kilogram than one that does not, and that is the part of the price the customs file registers without explaining. Dr.Groot On the brand side the same discipline applies. Dr.Groot, from LG H&H, has been in 682 Costco stores in the United States since September last year and entered Sephora in March 2026. The company announced that it won Best Fine Hair Shampoo & Conditioner at the Allure 2026 Best of Beauty Awards, the brand’s first such win. LG H&H’s own position moved with it. North American revenue in the first half of 2026 was 395.6 billion won, about $294 million, up 33.0%, ahead of China at 323.7 billion won. North America’s share of total revenue rose from 9.0% to 12.2%. Kerasys, from Aekyung Industrial, was in about 390 Walmart stores in the United States as of March 2026. Amorepacific sells hair care in 17 countries, and its Mise en scène Perfect Serum ranked first in Amazon’s hair oil category during the Big Spring Sale. Ryo’s growth in China was described as steady when it was last reported in March 2026, with no figure attached. Gravity, from Polyphenol Factory, reports cumulative sales of 1.85 million bottles within two years of launch — again, the company’s own count. Kerasys Does a higher price per kilogram mean a better business? Not on its own. Shampoo is mostly water in a heavy bottle; lip makeup is light and dense in value. $6.00 against $55.10 a kilogram says nothing about margin, and the two numbers should not be read against each other directly. What survives the comparison is direction within each line, measured against its own prior year. Shampoo’s buyers accepted a 20.3% higher price and took 12.8% more volume anyway. Lip makeup’s buyers took 18.4% more volume and paid 11.5% less for it. One further caution. HS 3305 is a tariff line, not a brand. It holds salon and mass products, private label and own-brand, premium and bulk, in the same number. A rising line average can mean a better mix or simply fewer low-price bulk shipments. The country detail — a 24.7% price rise in the United States, 43.9% in China on falling volume — points to mix. The customs data cannot settle it alone. What this leaves for manufacturing, brands and buyers For manufacturers, the argument for a higher price is a patent file and a laboratory result rather than a label. That is slower to build than a campaign and harder to copy once built. For brands, the uncomfortable reading is that the line gaining price is the one with the least brand recognition abroad, and the line losing it is the one with the most. Recognition and pricing power are not the same asset. For buyers and retailers, the arithmetic has changed on both shelves. Hair care costs more per unit than it did and still moves. Lip makeup costs less and needs more units to stand still. The customs file does not say which of those holds. It says which one is happening.